Tendencias de la evidencia científica de las evaluaciones económicas y las enfermedades no transmisibles: un análisis bibliométrico
Resumen
el envejecimiento de la población a nivel global ha generado un creciente interés en el estudio de las Enfermedades No Transmisibles (ENT) y la necesidad de evaluar económicamente su abordaje, dado su impacto en la mortalidad. El objetivo de este estudio es analizar la producción científica de evaluaciones económicas de las ENT y detectar áreas de investigación menos exploradas. Se llevó a cabo una búsqueda de la literatura en Web of Science (WoS), PubMed y Scopus. Se utilizó R/Bibliometrix y VosViewer para el análisis de datos. Los resultados revelaron un incremento en la producción científica a lo largo del tiempo. La revista “Value in Health” se destacó por ser la que más publicaciones ha realizado y los autores Mark Lamotte y Lieven Annemans fueron los que más publicaron. Los principales nodos de información estuvieron relacionados con diabetes en las ENT y con carga de enfermedad y costo-efectividad en las evaluaciones económicas. En conclusión, la producción científica relacionada con las evaluaciones económicas de las ENT se enfoca predominantemente en el análisis de los costos directos asociados a estas enfermedades y a los subanálisis de los Estudios de la Carga Global de Enfermedad.
Descargas
Referencias bibliográficas
United Nations, Department of Economic and Social Affairs. World Population Prospects 2019: Highlights. Disponible en: https://population.un.org/wpp/Publications/Files/WPP2019_Highlights.pdf
Vollset SE, et al. Fertility, Mortality, Migration, and Population Scenarios for 195 Countries and Territories from 2017 to 2100: A Forecasting Analysis for the Global Burden of Disease Study. The Lancet. [Internet].2020;396(10258):1285-306.https://doi.org/10.1016/S0140-6736(20)30677-2
Scott AJ. The Longevity Society. The Lancet Healthy Longevity [Internet]. 2021;2(12):e820-7. https://doi.org/10.1016/S2666-7568(21)00247-6
World Health Organization. The top 10 Causes of Death [Visitada en 2022 Enero 23]. Disponible en: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
Etienne CF. Promover la información sobre la economía de las enfermedades no transmisibles en la Región de las Américas*. Rev Panam Salud Publica.[Internet]. 2018 Jun;42:e94. https://doi.org/10.26633/RPSP.2018.94
Dang A, Likhar N, Alok U. Importance of Economic Evaluation in Health Care: An Indian Perspective.Value Health Reg Issues. [Internet]. 2016 May;9:78-83.https://doi.org/10.1016/j.vhri.2015.11.005
Ruiz A, Morillo L. Epidemiología clínica: investigación clínica aplicada. Bogotá: Editorial Médica Panamericana;2004.
Yousefi M, et al. Household Health Costs: Direct, Indirect, and Intangible. Iran J Public Health. [Internet].2014 Feb;43(2):202-209. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450688/
Donthu N, et al. How to Conduct a Bibliometric Analysis: An Overview and Guidelines. J Bus Res. [Internet].2021Sep;133:285-96. https://doi.org/10.1016/j.jbusres.2021.04.070
Van Eck NJ, Waltman L. Software Survey: VOSviewer,a Computer Program for Bibliometric Mapping. Scientometrics.[Internet]. 2010;84(2):523-538. https://doi.org/10.1007/s11192-009-0146-3
Salinas DT. Bibliometrix: Primeros pasos y técnicas avanzadas con BiblioShiny App. Zenodo; 2020.
Aria M, Cuccurullo C. Bibliometrix: An R-tool for Comprehensive Science Mapping Analysis. J Informetr.[Internet]. 2017 Nov;11(4):959-75. https://doi.org/10.1016/j.joi.2017.08.007
Mulugeta W, et al. Disease Burdens and Risk Factors for Diabetes, Hypertension, and Hyperlipidemia among Refugees in Buffalo, New York, 2004-2014. J Health Care Poor Underserved. [Internet]. 2019;30(3):1119-1131. https://doi.org/10.1353/hpu.2019.0077
Park J, et al. High Out-of-pocket Health Care Cost Burden Among Medicare Beneficiaries with Diabetes,1999-2017. Diabetes Care. [Internet]. 2021;44(8):1797-1804. https://doi.org/10.2337/dc20-2708
Wang Y, et al. National Trends in Out-of-Pocket Costs Among U.S. Adults with Diabetes Aged 18-64 Years:2001-2017. Diabetes Care. [Internet]. 2021;44(11):2510-2517. https://doi.org/10.2337/dc20-2833
Wang H, et al. Cost-utility of Afatinib and Gefitinib as First-Line Treatment for EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. Future Oncol. [Internet]. 2019;15(2):181-191. https://doi.org/10.2217/fon-2018-0692
Wang Y, et al. Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US. Front Public Health. [Internet].2021;9:650392. https://doi.org/10.3389/fpubh.2021.650392
Wimo A, et al. An Economic Evaluation of Donepezil in Mild to moderate Alzheimer’s Disease: Results of a 1-year, Double-Blind, Randomized Trial [published correction appears in Dement Geriatr Cogn Disord. 2003;16(2):102]. Dement Geriatr Cogn Disord. [Internet]. 2003;15(1):44-54. https://doi.org/10.1159/000066669
Wimo A, et al. Resource Utilization and Cost Analysi of Memantine in Patients with Moderate to Severe Alzheimer’s Disease. Pharmacoeconomics. [Internet].2003;21(5):327-340. https://doi.org/10.2165/00019053-200321050-00004
Handels RLH, et al. Cost-Utility of Using Alzheimer’s Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia.J Alzheimers Dis. [Internet]. 2017;60(4):1477-1487. https://doi.org/10.3233/JAD-170324
Handels RLH, et al. Early Cost-Utility Analysis of General and Cerebrospinal Fluid-specific Alzheimer’s Disease Biomarkers for Hypothetical Disease-Modifying Treatment Decision in Mild Cognitive Impairment. Alzheimer’s & Dementia [Internet]. 2015;11(8):896-905. https://doi.org/10.1016/j.jalz.2015.02.009
Vossius C, et al. Cost Analysis of Day Care Centres in Norway. PLoS One. [Internet]. 2019 Ago 8;14(8):e0219568. https://doi.org/10.1371/journal.pone.0219568
Wimo A, et al. Cost-utility Analysis of Group Living in Dementia Care. Int J Technol Assess Health Care.[Internet]. 1995;11(1):49-65. https://doi.org/10.1017/s0266462300005250
Robles-Zurita JA, et al. Economic Evaluation of Culprit Lesion only PCI vs. immediate Multivessel PCI in Acute Myocardial Infarction Complicated by Cardiogenic Shock: the Culprit-Shock Trial. Eur J Health Econ. [Internet]. 2020;21(8):1197-1209.https://doi.org/10.1007/s10198-020-01235-3
Wolowacz S, et al. Development and Validation of a Cost-Utility Model for Type 1 Diabetes Mellitus. Diabet Med. [Internet]. 2015;32(8):1023-1035. https://doi.org/10.1111/dme.12663
Cooper JT, et al. Health Related Quality of Life Utility Weights for Economic Evaluation through Different Stages of Chronic Kidney Disease: a Systematic Literature Review. Health Qual Life Outcomes. [Internet]. 2020 Sep 21;18(1):310.https://doi.org/10.1186/s12955-020-01559-x
Xin Y, et al. Type 2 Diabetes Remission: Economic Evaluation of the DiRECT/Counterweight-Plus Weight Management Programme within a Primary Care Randomized Controlled Trial. Diabet Med. [Internet].2019;36(8):1003-1012.https://doi.org/10.1111/dme.13981
Lamotte M, et al. A Multi-Country Economic Evaluation of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease. Pharmacoeconomics. [Internet]. 2006;24(2):155-169. https://doi.org/10.2165/00019053-200624020-00005
Annemans L, et al. Health Economic Evaluation of Controlled and Maintained Physical Exercise in the Prevention of Cardiovascular and other Prosperity Diseases. Eur J Cardiovasc Prev Rehabil. [Internet].2007;14(6):815-824. https://doi.org/10.1097/HJR.0b013e3282ef514f
Tsutani K, et al. A Health Economic Evaluation of Aspirin in the Primary Prevention of Cardiovascular Disease in Japan. Intern Med. [Internet].2007;46(4):157-162. https://doi.org/10.2169/internalmedicine.46.1843
Wilson K, et al. An Economic Evaluation based on a Randomized Placebo-Controlled Trial of Varenicline in Smokers with Cardiovascular Disease: Results for Belgium, Spain, Portugal, and Italy. Eur J Prev Cardiol. [Internet]. 2012;19(5):1173-1183. https://doi.org/10.1177/1741826711420345
Kotseva K, et al. Patient and Caregiver Productivity Loss and Indirect Costs Associated with Cardiovascular Events in Europe. Eur J Prev Cardiol.[Internet]. 2019;26(11):1150-1157. https://doi.org/10.1177/2047487319834770
GBD 2017 DALYs and HALE Collaborators. Global,Regional, and National Disability-Adjusted Life-Years (DALYs) for 359 Diseases and Injuries and HealthyLife Expectancy (HALE) for 195 Countries and Territories,1990-2017: A Systematic Analysis for the Global
Burden of Disease Study 2017 [published correction appears in Lancet. 2019 Jun 22;393(10190):e44]. Lancet.[Internet]. 2018;392(10159):1859-1922. https://doi.org/10.1016/S0140-6736(18)32335-3
Theodoratou D, et al. Analysis of Published Economic Evaluations of Angiotensin Receptor Blockers. Hellenic J Cardiol. [Internet]. 2009 Mar-Abr;50(2):105-118.Disponible en: https://pubmed.ncbi.nlm.nih.gov/19329412/
Maniadakis N, et al. Economic Evaluation of Irbesartan in Combination with Hydrochlorothiazide in the Treatment of Hypertension in Greece. Eur J Health Econ. [Internet]. 2011;12(3):253-261. https://doi.org/10.1007/s10198-010-0243-5
Fragoulakis V, Kourlaba G, Maniadakis N. Economic Evaluation of Statins in High-risk Patients Treated for Primary and Secondary Prevention of Cardiovascular Disease in Greece. Clinicoecon Outcomes Res. [Internet]. 2012;4:135-143. https://doi.org/10.2147/CEOR.S31376
Palmer AJ, et al. Cost-effectiveness of Detemir-Based Basal/Bolus Therapy versus NPH-based Basal/Bolus Therapy for Type 1 diabetes in a UK Setting:An Economic Analysis Based on Meta-Analysis Results of four Clinical Trials. Curr Med Res Opin.[Internet]. 2004;20(11):1729-1746. https://doi.org/10.1185/030079904X5661
Sivignon M, et al. Health-economic Evaluation of Lung Cancer Drugs: do s and don ts in France. Value in Health. [Internet]. 2019; 22:S455. https://doi.org/10.1016/j.jval.2019.09.297
Lamotte M, et al. A Health Economic Evaluation of Concomitant Surgical Ablation for Atrial Fibrillation.Eur J Cardiothorac Surg. [Internet]. 2007;32(5):702-710. https://doi.org/10.1016/j.ejcts.2007.07.027
GBD 2017 DALYs and HALE Collaborators. Global,Regional, and National Disability-Adjusted Life-Years (DALYs) for 359 Diseases and Injuries and Healthy Life Expectancy (HALE) for 195 Countries And Territories,1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017 [published correction appears in Lancet. 2019 Jun 22;393(10190):e44]. Lancet.[Internet].2018;392(10159):1859-1922. https://doi.org/10.1016/S0140-6736(18)32335-3
GBD 2013 DALYs and HALE Collaborators. Global, Regional, and National Disability-Adjusted Life-Years (DALYs) for 306 Diseases and Injuries and Healthy Life Expectancy (HALE) for 188 countries, 1990-2013: Quantifying the Epidemiological Transition. Lancet.[Internet]. 2015;386(10009):2145-2191. https://doi.org/10.1016/S0140-6736(15)61340-X
GBD 2015 DALYs and HALE Collaborators. Global,Regional, and National Disability-Adjusted Life-Years (DALYs) for 315 Diseases and Injuries and Healthy Life Expectancy (HALE), 1990-2015: A Systematic Analysis for the Global Burden of Disease Study 2015 [published correction appears in Lancet. 2017 Jan 7;389(10064):e1].Lancet. [Internet]. 2016;388(10053):1603-1658. Diseases and Injuries and Healthy Life Expectancy https://doi.org/10.1016/S0140-6736(16)31460-X
GBD 2015 DALYs and HALE Collaborators. Global,Regional, and National Disability-Adjusted Life-Years (DALYs) for 315 Diseases and Injuries and Healthy Life Expectancy (HALE), 1990-2015: A Systematic Analysis for the Global Burden of Disease Study 2015 [published correction appears in Lancet. 2017 Jan 7;389(10064):e1].Lancet. [Internet]. 2016;388(10053):1603-1658.https://doi.org/10.1016/S0140-6736(16)31460-X
Murray CJ, et al. Disability-adjusted Life Years (DALYs) for 291 Diseases and Injuries in 21 Regions, 1990-2010: A Systematic Analysis for the Global Burden of Disease Study 2010 [published correction appears in Lancet.[Internet]. 2013; 380(9859):2197-2223. https://doi.org/10.1016/S0140-6736(12)61689-4
Aghaei Chadegani A, et al. A Comparison Between two Main Academic Literature Collections: Web of Science and Scopus Databases. Asian Social Science [Internet]. 2013;9(5):18-26. https://doi.org/10.5539/ass.v9n5p18
Zhu J, Liu W. A Tale of two Databases: the use of Web of Science and Scopus in Academic Papers. Scientometrics.[Internet]. 2020;123(1):321-35. https://doi.org/10.1007/s11192-020-03387-8
National Center for Biotechnology information (NCBI). National Library of Medicine. PubMed [Visitada en 2022 Jul 3]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/
Palmer AJ, et al. An Economic Evaluation of Irbesartan in the Treatment of Patients with type 2 Diabetes, Hypertension and Nephropathy: Cost-Effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings. Nephrol Dial Transplant. [Internet]. 2003;18(10):2059-2066. https://doi.org/10.1093/ndt/gfg232
World University Rankings. QS World University Rankings 2022: Top Global Universities | Top Universities. 2022. [Visitada en 2022 Jul 3]. Disponible en: https://www.topuniversities.com/university-rankings/world-university-rankings/2022
Muñoz PAE, Casallas MIR. Relación entre felicidad en el trabajo y desempeño laboral: análisis bibliométrico, evolución y tendencias. Revista Virtual Universidad Católica del Norte. [Internet]. 2021;(64):241-80. https://doi.org/10.35575/rvucn.n64a10
Derechos de autor 2023 Revista Med
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
.png)
